Ankh Life Sciences

Ankh Life Sciences is a biotechnology company dedicated to developing first-in-class therapeutics for systemic calcification and age-related diseases. The company's primary focus is the modulation of the ANKH protein, a transmembrane transporter of inorganic pyrophosphate (ePPi), which is a potent inhibitor of hydroxyapatite crystallization. By targeting ANKH, the company aims to restore phosphate homeostasis and prevent pathological mineralization in conditions such as vascular calcification and osteoarthritis. Ankh Life Sciences is currently advancing its lead small molecule programs through pre-clinical development. The company is backed by prominent longevity-focused investors and leverages deep expertise in metabolic and mineral biology.